IP Library › Granted Patent US 7,744,618
Granted Patent B2
US 7,744,618 · App. 11/567,907 · Granted Jun 29, 2010

Device and method for modulating renal function

Assignee: Cardiac Pacemakers, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,744,618
App. No.
11/567,907
Granted
Jun 29, 2010
Kind
B2
Abstract

Renal function may be modulated by an implantable device having one or more leads or catheters disposed near the kidney via the lymphatic system. In one embodiment, lymphatic drainage from the kidney is modulated to increase or decrease tubular reabsorption of salt and water. The renal function modulation therapy may be delivered in an open-loop or closed-loop fashion, with the latter dependent upon a physiological variable such as blood pressure or cardiac output.

Claims (14)

1. A method, comprising:

implanting an implantable device having a controller and a means operable by the controller for delivering a renal function modulation therapy wherein the renal function modulation therapy delivery includes obstructing renal lymphatic flow;

configuring the controller to receive a blood pressure measurement from a blood pressure sensor; and,

configuring the controller to obstruct renal lymphatic flow in response to the blood pressure measurement exceeding a specified limit value.

2. The method of claim 1 further comprising introducing a catheter or lead connected to the therapy delivery means into the patient's lymphatic system and routing the catheter or lead to an appropriate site for affecting renal function.

3. The method of claim 1 wherein the renal function modulation therapy comprises augmenting renal lymphatic flow.

4. The method of claim 1 wherein the renal function modulation therapy comprises delivery of a drug directly to the kidney by retrograde infusion through a lymphatic vessel.

5. The method of claim 1 wherein the renal function modulation therapy comprises inhibition or stimulation of a renal nerve or other site affecting renal sympathetic stimulation.

6. The method of claim 1 further comprising programming the controller to deliver renal function modulation therapy upon receipt of a command to do so via telemetry.

7. The method of claim 1 wherein the implantable device includes a sensor for measuring a physiological variable and further comprising programming the device controller to deliver renal function modulation therapy in closed-loop fashion in dependence upon the measured physiological variable.

8. The method of claim 7 wherein the renal function modulation therapy further comprises augmenting renal lymphatic flow and wherein the physiological variable is blood pressure.

9. The method of claim 7 wherein the renal function modulation therapy comprises blocking renal lymphatic flow and wherein the physiological variable is cardiac output.

10. The method of claim 7 wherein the renal function modulation therapy comprises blocking renal lymphatic flow and wherein the physiological variable is a cardiac function index that reflects the adequacy of cardiac output for a particular exertion level.

11. The method of claim 7 wherein the physiological variable is selected from a group that includes blood pressure, cardiac output, transthoracic impedance, exertion level, blood pH, blood osmolarity, and blood electrolyte concentration.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2007
From: SHUROS, ALLAN C.; BROOKE, M. JASON; POONAWALA, TASNEEM
To: CARDIAC PACEMARKER, INC.
Reel/Frame 019150/0833 →
Continuity (1)
Related Publication 20080140000A1 · Jun 12, 2008